Cargando…
Multiple Intravenous Administrations of Human Umbilical Cord Blood Cells Benefit in a Mouse Model of ALS
BACKGROUND: A promising therapeutic strategy for amyotrophic lateral sclerosis (ALS) is the use of cell-based therapies that can protect motor neurons and thereby retard disease progression. We recently showed that a single large dose (25×10(6) cells) of mononuclear cells from human umbilical cord b...
Autores principales: | Garbuzova-Davis, Svitlana, Rodrigues, Maria C. O., Mirtyl, Santhia, Turner, Shanna, Mitha, Shazia, Sodhi, Jasmine, Suthakaran, Subatha, Eve, David J., Sanberg, Cyndy D., Kuzmin-Nichols, Nicole, Sanberg, Paul R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272008/ https://www.ncbi.nlm.nih.gov/pubmed/22319620 http://dx.doi.org/10.1371/journal.pone.0031254 |
Ejemplares similares
-
Human Umbilical Cord Blood Treatment in a Mouse Model of ALS: Optimization of Cell Dose
por: Garbuzova-Davis, Svitlana, et al.
Publicado: (2008) -
Blood-brain barrier impairment in MPS III patients
por: Garbuzova-Davis, Svitlana, et al.
Publicado: (2013) -
Plasma derived from human umbilical cord blood: Potential cell‐additive or cell‐substitute therapeutic for neurodegenerative diseases
por: Ehrhart, Jared, et al.
Publicado: (2018) -
Reduction of microhemorrhages in the spinal cord of symptomatic ALS mice after intravenous human bone marrow stem cell transplantation accompanies repair of the blood-spinal cord barrier
por: Eve, David J., et al.
Publicado: (2018) -
Blood-CNS Barrier Impairment in ALS patients versus an animal model
por: Garbuzova-Davis, Svitlana, et al.
Publicado: (2014)